Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis
1. The FDA has expanded the label for guselkumab (Tremfya) to include evidence that it can inhibit progression of structural ...
Tag: psoriatic arthritis
![2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]](https://www.2minutemedicine.com/wp-content/uploads/2025/05/ChatGPT-Image-May-12-2025-at-10_22_23-AM-350x250.png)
2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis
Pfizer and Innovent deepen the China biotech licensing wave Pfizer is making another large oncology bet, this time through a ...
Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis
1. Time to disease flare was significantly shorter in the placebo group versus baricitinib. 2. There was no difference in ...
Bimekizumab is effective for active psoriatic arthritis in biologic-naïve adults
1. Significantly more patients in the bimekizumab group reached ACR50 at week 16 compared to the placebo. 2. Fungal infections ...
#VisualAbstract: Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis
1. Patients in the tofacitinib group reported significantly fewer flare-ups (29%) compared to placebo (53%) by week 44. 2. The ...
Tofacitinib reduces the rate of flare-ups in patients with polyarticular juvenile idiopathic arthritis
1. Patients in the tofacitinib group reported significantly fewer flare-ups (29%) compared to placebo (53%) by week 44. 2. The ...
Upadacitinib non-inferior to adalimumab for psoriatic arthritis treatment
1. Janus kinase (JAK) inhibitor upadacitinib showed non-inferior efficacy in improving psoriatic arthritis compared to standard-of-care adalimumab. 2. High-dose upadacitinib ...
